SETTING: The country of Georgia has a high burden of multi- (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). OBJECTIVE: To assess the performance of the GenoType® MTBDRsl assay in the detection of resistance to kanamycin (KM), capreomycin (CPM) and ofloxacin (OFX), and of XDR-TB. DESIGN: Consecutive acid-fast bacilli smear-positive sputum specimens identified as MDR-TB using the MTBDRplus test were evaluated with the MTBDRsl assay and conventional second-line drug susceptibility testing (DST). RESULTS: Among 159 specimens, amplification was adequate in 154 (97%), including 9 of 9 culture-negative and 2 of 3 contaminated specimens. Second-line DST revealed that 17 (12%) Mycobacterium tuberculosis isolates were XDR-TB. Compared to DST, the MTBDRsl had 41% sensitivity and 98% specificity in detecting XDR-TB and 81% sensitivity and 99% specificity in detecting OFX resistance. Sensitivity was low in detecting resistance to KM (29%) and CPM (57%), while specificity was respectively 99% and 94%. Median times from sputum collection to second-line DST and MTBDRsl results were 70-104 vs. 10 days. CONCLUSION: Although the MTBDRsl assay had a rapid turnaround time, detection of second-line drug resistance was poor compared to DST. Further genetic mutations associated with resistance to second-line drugs should be included in the assay to improve test performance and clinical utility.
SETTING: The country of Georgia has a high burden of multi- (MDR-TB) and extensively drug-resistant tuberculosis (XDR-TB). OBJECTIVE: To assess the performance of the GenoType® MTBDRsl assay in the detection of resistance to kanamycin (KM), capreomycin (CPM) and ofloxacin (OFX), and of XDR-TB. DESIGN: Consecutive acid-fast bacilli smear-positive sputum specimens identified as MDR-TB using the MTBDRplus test were evaluated with the MTBDRsl assay and conventional second-line drug susceptibility testing (DST). RESULTS: Among 159 specimens, amplification was adequate in 154 (97%), including 9 of 9 culture-negative and 2 of 3 contaminated specimens. Second-line DST revealed that 17 (12%) Mycobacterium tuberculosis isolates were XDR-TB. Compared to DST, the MTBDRsl had 41% sensitivity and 98% specificity in detecting XDR-TB and 81% sensitivity and 99% specificity in detecting OFX resistance. Sensitivity was low in detecting resistance to KM (29%) and CPM (57%), while specificity was respectively 99% and 94%. Median times from sputum collection to second-line DST and MTBDRsl results were 70-104 vs. 10 days. CONCLUSION: Although the MTBDRsl assay had a rapid turnaround time, detection of second-line drug resistance was poor compared to DST. Further genetic mutations associated with resistance to second-line drugs should be included in the assay to improve test performance and clinical utility.
Authors: S J Kim; M A Espinal; C Abe; G H Bai; F Boulahbal; L Fattorin; C Gilpin; S Hoffner; K M Kam; N Martin-Casabona; L Rigouts; V Vincent Journal: Int J Tuberc Lung Dis Date: 2004-09 Impact factor: 2.373
Authors: Paul A Harris; Robert Taylor; Robert Thielke; Jonathon Payne; Nathaniel Gonzalez; Jose G Conde Journal: J Biomed Inform Date: 2008-09-30 Impact factor: 6.317
Authors: David J Horne; Lancelot M Pinto; Matthew Arentz; S-Y Grace Lin; Edward Desmond; Laura L Flores; Karen R Steingart; Jessica Minion Journal: J Clin Microbiol Date: 2012-11-14 Impact factor: 5.948
Authors: Ibrahim Abubakar; Matteo Zignol; Dennis Falzon; Mario Raviglione; Lucica Ditiu; Susan Masham; Ifedayo Adetifa; Nathan Ford; Helen Cox; Stephen D Lawn; Ben J Marais; Timothy D McHugh; Peter Mwaba; Matthew Bates; Marc Lipman; Lynn Zijenah; Simon Logan; Ruth McNerney; Adam Zumla; Krishna Sarda; Payam Nahid; Michael Hoelscher; Michel Pletschette; Ziad A Memish; Peter Kim; Richard Hafner; Stewart Cole; Giovanni Battista Migliori; Markus Maeurer; Marco Schito; Alimuddin Zumla Journal: Lancet Infect Dis Date: 2013-03-24 Impact factor: 25.071
Authors: D C Richards; T Mikiashvili; J J Parris; E V Kourbatova; J C E Wilson; N Shubladze; T Tsertvadze; G Khechinashvili; C del Rio; H M Blumberg Journal: Int J Tuberc Lung Dis Date: 2006-04 Impact factor: 2.373
Authors: William A Wells; Catharina C Boehme; Frank G J Cobelens; Colleen Daniels; David Dowdy; Elizabeth Gardiner; Jan Gheuens; Peter Kim; Michael E Kimerling; Barry Kreiswirth; Christian Lienhardt; Khisi Mdluli; Madhukar Pai; Mark D Perkins; Trevor Peter; Matteo Zignol; Alimuddin Zumla; Marco Schito Journal: Lancet Infect Dis Date: 2013-03-24 Impact factor: 25.071
Authors: N Bablishvili; N Tukvadze; E Shashkina; B Mathema; N R Gandhi; H M Blumberg; R R Kempker Journal: Antimicrob Agents Chemother Date: 2017-08-24 Impact factor: 5.191
Authors: Nestan Tukvadze; Ekaterina Sanikidze; Maia Kipiani; Gautam Hebbar; Kirk A Easley; Neeta Shenvi; Russell R Kempker; Jennifer K Frediani; Veriko Mirtskhulava; Jessica A Alvarez; Nino Lomtadze; Lamara Vashakidze; Li Hao; Carlos Del Rio; Vin Tangpricha; Henry M Blumberg; Thomas R Ziegler Journal: Am J Clin Nutr Date: 2015-09-23 Impact factor: 7.045
Authors: Sarah Sengstake; Nino Bablishvili; Anja Schuitema; Nino Bzekalava; Edgar Abadia; Jessica de Beer; Nona Tadumadze; Maka Akhalaia; Kiki Tuin; Nestani Tukvadze; Rusudan Aspindzelashvili; Elizabeta Bachiyska; Stefan Panaiotov; Christophe Sola; Dick van Soolingen; Paul Klatser; Richard Anthony; Indra Bergval Journal: BMC Genomics Date: 2014-07-07 Impact factor: 3.969
Authors: Rebecca E Colman; Julia Anderson; Darrin Lemmer; Erik Lehmkuhl; Sophia B Georghiou; Hannah Heaton; Kristin Wiggins; John D Gillece; James M Schupp; Donald G Catanzaro; Valeriu Crudu; Ted Cohen; Timothy C Rodwell; David M Engelthaler Journal: J Clin Microbiol Date: 2016-05-25 Impact factor: 5.948
Authors: A H Van't Hoog; I Bergval; N Tukvadze; S Sengstake; R Aspindzelashvili; R M Anthony; F Cobelens Journal: BMC Infect Dis Date: 2015-10-26 Impact factor: 3.090
Authors: Sophia B Georghiou; Marva Seifert; Shou-Yean Lin; Donald Catanzaro; Richard S Garfein; Roberta L Jackson; Valeriu Crudu; Camilla Rodrigues; Thomas C Victor; Antonino Catanzaro; Timothy C Rodwell Journal: BMC Infect Dis Date: 2016-08-31 Impact factor: 3.090